{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["60(5)"],"submitter":["Mascarenhas J"],"funding":["NHLBI NIH HHS","National Cancer Institute","NCI NIH HHS"],"journal":["Leukemia & lymphoma"],"pagination":["1343-1345"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6530779"],"repository":["biostudies-literature"],"pubmed_title":["Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis."],"pmcid":["PMC6530779"],"funding_grant_id":["P01CA108671","P01 HL053762","P01 CA108671"],"pubmed_authors":["Weinberg R","Dueck AC","Price L","Mascarenhas J","Tremblay D","Hexner E","Sandy L","Goldberg JD","Silverman LR","Kessler C","Kosiorek H","Pahl H","Hoffman R","Baer MR"],"additional_accession":[]},"is_claimable":false,"name":"Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.","description":null,"dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2026-05-02T00:09:54.559Z","creation":"2025-04-21T16:06:03.383Z"},"accession":"S-EPMC6530779","cross_references":{"pubmed":["30668266"],"doi":["10.1080/10428194.2018.1532509"]}}